Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO-Reference-Cited by-同舟云学术

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO

Published:2021-12 Issue:6 Volume:6 Page:100293
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Rossini D.,Boccaccino A.,Sbrana A.,Daniel F.,Borelli B.,Raimondi A.,Santini D.,Conca V.,Tomasello G.,Caponnetto S.,Marmorino F.,Zaniboni A.,Buonadonna A.,Masi G.,Lonardi S.,Pietrantonio F.,Falcone A.,Antonuzzo A.,Cremolini C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med,2014

2. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials;Cremolini;Ann Oncol,2016

3. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

4. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer;Cremolini;J Clin Oncol,2020

5. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients;Kuderer;Cancer,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of clinical and translational research on the quality of life during the metastatic colorectal cancer patient journey;Frontiers in Oncology;2023-10-16

2. Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials;European Journal of Cancer;2023-08

3. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer;Nature;2023-02-22